Overview

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Status:
Completed

Trial end date:
2013-10-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy. This study will also assess the effect of 12 weeks of treatment with solifenacin succinate versus placebo on quality of life (QOL) as measured by questionnaires.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Solifenacin Succinate